Description

Certara, Inc.: Will Its Integration & Expansion via Strategic Acquisitions Be A Breakthrough Move? 

Certara’s latest quarterly earnings reveal a mixed set of financial and operational conditions that provide both promising prospects and certain challenges. The company reported third-quarter revenue of $94.8 million, an 11% year-over-year increase. This was bolstered by a 13% rise in total bookings, signaling a steady demand for Certara’s biosimulation services in the global drug development industry. A key positive development was the closing of the Chemaxon acquisition, aimed at expanding Certara’s biosimulation capabilities into the preclinical market. By integrating Chemaxon’s chemical property calculation and simulation tools with Certara’s existing capabilities, the company aims to develop a more comprehensive biosimulation platform. Additionally, Certara exhibited high win rates and a strong pipeline, pointing to robust demand for their solutions.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!